

## Highlights of This Issue 1235

## SPECIAL FEATURES

CCR 20<sup>th</sup> Anniversary Commentary

- 1237** CCR 20<sup>th</sup> Anniversary Commentary: BMS-247550—Microtubule Stabilization as Successful Targeted Therapy  
Navjotsingh Pabla and Alex Sparreboom

## CCR Translations

- 1240** Steroid Sidestep: Evading Androgen Ablation by Abiraterone  
Nima Sharifi  
*See related article, p. 1273*

## Molecular Pathways

- 1243** Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response  
Elda Grabocka, Cosimo Commisso, and Dafna Bar-Sagi

## Reviews

- 1248** Interleukin-6 as a Therapeutic Target  
Jean-François Rossi, Zhao-Yang Lu, Michel Jourdan, and Bernard Klein
- 1258** Translational Implications of Tumor Heterogeneity  
 Mariam Jamal-Hanjani, Sergio A. Quezada, James Larkin, and Charles Swanton

## CLINICAL TRIAL BRIEF REPORT

- 1267** Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies  
Veronika Bachanova, Arthur E. Frankel, Qing Cao, Dixie Lewis, Bartosz Grzywacz, Michael R. Verneris, Celalettin Ustun, Aleksandr Lazaryan, Brian McClune, Erica D. Warlick, Hagop Kantarjian, Daniel J. Weisdorf, Jeffrey S. Miller, and Daniel A. Vallera

## CANCER THERAPY: CLINICAL

- 1273** Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors  
Eddy J. Chen, Adam G. Sowalsky, Shuai Gao, Changmeng Cai, Olga Voznesensky, Rachel Schaefer, Massimo Loda, Lawrence D. True, Huihui Ye, Patricia Troncoso, Rosina L. Lis, Philip W. Kantoff, Robert B. Montgomery, Peter S. Nelson, Glenn J. Bubley, Steven P. Balk, and Mary-Ellen Taplin  
*See related commentary, p. 1240*
- 1281**  A First-in-Human Phase I Study of MORAB-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors  
Luis A. Diaz Jr, Christina M. Coughlin, Susan C. Weil, Jean Fishel, Mrinal M. Gounder, Susan Lawrence, Nilofer Azad, Daniel J. O'Shannessy, Luigi Grasso, Jason Wustner, Wolfgang Ebel, and Richard D. Carvajal
- 1289** Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma  
Atsushi Otsuka, Jil Dreier, Phil F. Cheng, Mirjam Nägeli, Holger Lehmann, Lea Felderer, Ian J. Frew, Shigeto Matsushita, Mitchell P. Levesque, and Reinhard Dummer
- 1298** Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2<sup>+</sup> Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data  
Jean-Yves Pierga, Thierry Petit, Christelle Lévy, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Jacques Bonnetterre, Juana Hernandez, François-Clément Bidard, and Patrice Viens
- 1305** Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors  
Victoria Roulstone, Khurum Khan, Hardev S. Pandha, Sarah Rudman, Matt Coffey, George M. Gill, Alan A. Melcher, Richard Vile, Kevin J. Harrington, Johann de Bono, and James Spicer
- 1313** Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients  
Rona Yaeger, Andrea Cercek, Eileen M. O'Reilly, Diane L. Reidy, Nancy Kemeny, Tamar Wolinsky, Marinela Capanu, Marc J. Gollub, Neal Rosen, Michael F. Berger, Mario E. Lacouture, Efsevia Vakiani, and Leonard B. Saltz



# Table of Contents

- 1321** **Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study**  
 Peter Johnson, Ruth Challis, Ferdousi Chowdhury, Yifang Gao, Melanie Harvey, Tom Geldart, Paul Kerr, Claude Chan, Anna Smith, Neil Steven, Ceri Edwards, Margaret Ashton-Key, Elisabeth Hodges, Alison Tutt, Christian Ottensmeier, Martin Glennie, and Anthony Williams

## PERSONALIZED MEDICINE AND IMAGING

- 1329** **Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting**  
Benoit Beuselinck, Sylvie Job, Etienne Becht, Alexandra Karadimou, Virginie Verkarre, Gabrielle Couchy, Nicolas Giraldo, Nathalie Rioux-Leclercq, Vincent Molinié, Mathilde Sibony, Reza Elaidi, Corinne Teghom, Jean-Jacques Patard, Arnaud Méjean, Wolf Herman Fridman, Catherine Sautés-Fridman, Aurélien de Reyniès, Stéphane Oudard, and Jessica Zucman-Rossi
- 1340** **Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degradator**  
Pedram Heidari, Francis Deng, Shadi A. Esfahani, Alicia K. Leece, Timothy M. Shoup, Neil Vasdev, and Umar Mahmood
- 1348** **Potential Role of pNF-H, a Biomarker of Axonal Damage in the Central Nervous System, as a Predictive Marker of Chemotherapy-Induced Cognitive Impairment**  
Akina Natori, Toru Ogata, Masahiko Sumitani, Takamichi Kogure, Teruo Yamauchi, and Hideko Yamauchi
- 1353** **Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia**  
Daniel Steinbach, Peter Bader, Andre Willasch, Stephan Bartholomae, Klaus-Michael Debatin, Martin Zimmermann, Ursula Creutzig, Dirk Reinhardt, and Bernd Gruhn

## CANCER THERAPY: PRECLINICAL

- 1360** **Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations**  
Francesca Alvarez-Calderon, Mark A. Gregory, Catherine Pham-Danis, Deborah DeRyckere, Brett M. Stevens, Vadym Zaberezhnyy, Amanda A. Hill, Lelisa Gemta, Amit Kumar, Vijay Kumar, Michael F. Wempe, Daniel A. Pollyea, Craig T. Jordan, Natalie J. Serkova, Douglas K. Graham, and James DeGregori


- 1373** **Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents**  
Ana Teresa Amaral, Cecilia Garofalo, Roberta Frapolli, Maria Cristina Manara, Caterina Mancarella, Sarah Uboldi, Silvana Di Giandomenico, Jose Luis Ordóñez, Victoria Sevillano, Roberta Malaguarnera, Piero Picci, A. Bass Hassan, Enrique De Alava, Maurizio D'Incalci, and Katia Scotlandi

- 1383** **Antibody-Mediated Delivery of Anti-KRAS-siRNA *In Vivo* Overcomes Therapy Resistance in Colon Cancer**  
Sebastian Bäumer, Nicole Bäumer, Neele Appel, Lisa Terheyden, Julia Fremerey, Sonja Schelhaas, Eva Wardelmann, Frank Buchholz, Wolfgang E. Berdel, and Carsten Müller-Tidow

- 1395** **Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant *MLL*-Rearranged Acute Lymphoblastic Leukemia**  
Jennifer Richmond, Hernan Carol, Kathryn Evans, Laura High, Agnes Mendo, Alissa Robbins, Claus Meyer, Nicola C. Venn, Rolf Marschalek, Michelle Henderson, Rosemary Sutton, Raushan T. Kurmasheva, Ursula R. Kees, Peter J. Houghton, Malcolm A. Smith, and Richard B. Lock

- 1406** **Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase Expression**  
Alba Rodríguez-García, Marta Giménez-Alejandre, Juan J. Rojas, Rafael Moreno, Miriam Bazan-Peregrino, Manel Cascalló, and Ramon Alemany

## BIOLOGY OF HUMAN TUMORS

- 1419** **Cyclin-Dependent Kinase 5 Decreases in Gastric Cancer and Its Nuclear Accumulation Suppresses Gastric Tumorigenesis**  
 Longlong Cao, Jiechao Zhou, Junrong Zhang, Sijin Wu, Xintao Yang, Xin Zhao, Huifang Li, Ming Luo, Qian Yu, Guangtan Lin, Huizhong Lin, Jianwei Xie, Ping Li, Xiaoqing Hu, Chaohui Zheng, Guojun Bu, Yun-wu Zhang, Huaxi Xu, Yongliang Yang, Changming Huang, and Jie Zhang

- 1429** **A Comparative Study of Molecular Characteristics of Diffuse Large B-cell Lymphoma from Patients with and without Human Immunodeficiency Virus Infection**  
Chun Chao, Michael J. Silverberg, Lanfang Xu, Lie-Hong Chen, Brandon Castor, Otoniel Martínez-Maza, Donald I. Abrams, Hongbin D. Zha, Reina Haque, and Jonathan Said

# Table of Contents

**1438** Gain of HIF-1 $\alpha$  under Normoxia in Cancer Mediates Immune Adaptation through the AKT/ERK and VEGFA Axes

Young-Ho Lee, Hyun Cheol Bae, Kyung Hee Noh, Kwon-Ho Song, Sang-kyu Ye, Chih-Ping Mao, Kyung-Mi Lee, T.-C. Wu, and Tae Woo Kim

**1447** Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma

Yvonne Y. Li, Glenn J. Hanna, Alvaro C. Laga, Robert I. Haddad, Jochen H. Lorch, and Peter S. Hammerman

**1457** Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas

Ashley S. Margol, Nathan J. Robison, Janahan Gnanachandran, Long T. Hung, Rebekah J. Kennedy, Marzieh Vali, Girish Dhall, Jonathan L. Finlay, Anat Erdreich-Epstein, Mark D. Krieger, Rachid Drissi, Maryam Fouladi, Floyd H. Gilles, Alexander R. Judkins, Richard Sposto, and Shahab Asgharzadeh

**1466** Impaired Self-Renewal and Increased Colitis and Dysplastic Lesions in Colonic Mucosa of AKR1B8-Deficient Mice



Yi Shen, Jun Ma, Ruilan Yan, Hongyan Ling, Xiaoning Li, Wancai Yang, John Gao, Chenfei Huang, Yiwen Bu, Yu Cao, Yingchun He, Laxiang Wan, Xuyu Zu, Jianghua Liu, Mei Chris Huang, William F. Stenson, Duan-Fang Liao, and Deliang Cao

**1477** Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung



Maud HW. Starmans, Melania Pintilie, Michelle Chan-Seng-Yue, Nathalie C. Moon, Syed Haider, Francis Nguyen, Suzanne K. Lau, Ni Liu, Arek Kasprzyk, Bradly G. Wouters, Sandy D. Der, Frances A. Shepherd, Igor Jurisica, Linda Z. Penn, Ming-Sound Tsao, Philippe Lambin, and Paul C. Boutros

**1487** PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a  $\gamma$ -Secretase Inhibitor



Kai Wang, Qin Zhang, Danan Li, Keith Ching, Cathy Zhang, Xianxian Zheng, Mark Ozeck, Stephanie Shi, Xiaorong Li, Hui Wang, Paul Rejto, James Christensen, and Peter Olson

## LETTERS TO THE EDITOR

**1497** Pharmacogenomic Modeling in Pancreatic Cancer—Letter

Amir Avan, Abolfazl Avan, Mina Maftouh, Majid Ghayour Mobarhan, and Sharareh Gholamin

**1498** Pharmacogenomic Modeling in Pancreatic Cancer—Response

Kenneth H. Yu

## CORRECTIONS

**1499** Correction: Silencing of Human Phosphatidylethanolamine-Binding Protein 4 Sensitizes Breast Cancer Cells to Tumor Necrosis Factor- $\alpha$ -Induced Apoptosis and Cell Growth Arrest

**1502** Correction: *TP53* Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>


For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)



# Table of Contents

## ABOUT THE COVER

The cover shows a section of a skin biopsy from a basal cell carcinoma patient after hedgehog inhibitor treatment. Immunohistochemical staining reveals a post-therapy increase of peri- and intratumor CD4<sup>+</sup> T cells in the tumor area. For details, see the article by Otsuka and colleagues on page 1289 of this issue.



# Clinical Cancer Research

**21 (6)**

*Clin Cancer Res* 2015;21:1235-1502.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/21/6>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/21/6>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.